GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Mural Oncology PLC (NAS:MURA) » Definitions » Cash Ratio

Mural Oncology (Mural Oncology) Cash Ratio : 10.90 (As of Mar. 2024)


View and export this data going back to 2023. Start your Free Trial

What is Mural Oncology Cash Ratio?

The Cash Ratio measures a company’s ability to meet its short-term obligations with cash and near-cash resources. It is calculated as a company's Cash, Cash Equivalents, Marketable Securities divides by its Total Current Liabilities. Mural Oncology's Cash Ratio for the quarter that ended in Mar. 2024 was 10.90.

Mural Oncology has a Cash Ratio of 10.90. It generally indicates that the company is able to cover all short-term debt and still have cash remaining.

The historical rank and industry rank for Mural Oncology's Cash Ratio or its related term are showing as below:

MURA' s Cash Ratio Range Over the Past 10 Years
Min: 9.33   Med: 10.9   Max: 47.07
Current: 10.9

During the past 3 years, Mural Oncology's highest Cash Ratio was 47.07. The lowest was 9.33. And the median was 10.90.

MURA's Cash Ratio is ranked better than
83.05% of 1504 companies
in the Biotechnology industry
Industry Median: 2.94 vs MURA: 10.90

Mural Oncology Cash Ratio Historical Data

The historical data trend for Mural Oncology's Cash Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Mural Oncology Cash Ratio Chart

Mural Oncology Annual Data
Trend Dec21 Dec22 Dec23
Cash Ratio
- - 9.33

Mural Oncology Quarterly Data
Dec21 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cash Ratio Get a 7-Day Free Trial Premium Member Only - 47.07 - 9.33 10.90

Competitive Comparison of Mural Oncology's Cash Ratio

For the Biotechnology subindustry, Mural Oncology's Cash Ratio, along with its competitors' market caps and Cash Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Mural Oncology's Cash Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Mural Oncology's Cash Ratio distribution charts can be found below:

* The bar in red indicates where Mural Oncology's Cash Ratio falls into.



Mural Oncology Cash Ratio Calculation

The Cash Ratio measures a company's ability to meet its short-term obligations with its cash and near-cash resources.

Mural Oncology's Cash Ratio for the fiscal year that ended in Dec. 2023 is calculated as:

Cash Ratio (A: Dec. 2023 )=Cash, Cash Equivalents, Marketable Securities/Total Current Liabilities
=270.852/29.017
=9.33

Mural Oncology's Cash Ratio for the quarter that ended in Mar. 2024 is calculated as:

Cash Ratio (Q: Mar. 2024 )=Cash, Cash Equivalents, Marketable Securities/Total Current Liabilities
=231.674/21.247
=10.90

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Mural Oncology  (NAS:MURA) Cash Ratio Explanation

The cash ratio is more conservative than other liquidity ratios, such as Quick Ratio and Current Ratio, because it only considers a company's most liquid resources. The numerator of cash ratio only considers Cash, Cash Equivalents and marketable securities. Other current assets, such as accounts receivable and inventories, are not included. The rationale is that these assets may require time to be transformed into cash, and the amount of money received is also uncertain.

The cash ratio shows a company’s ability to pay all current liabilities immediately without selling or liquidating other assets. Generally speaking, a higher cash ratio suggests the company has a stronger ability to cover its short-term debt. However, a high cash ratio could also indicate inefficient management: the company is inefficient in making full utilization of cash to invest protential profitable project. It may also suggest that the company is not confident about future profitability.

In general, the higher the cash ratio, the better the company's liquidity position.


Mural Oncology Cash Ratio Related Terms

Thank you for viewing the detailed overview of Mural Oncology's Cash Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Mural Oncology (Mural Oncology) Business Description

Comparable Companies
Traded in Other Exchanges
N/A
Address
10 Earlsfort Terrace, Dublin, IRL, D02 T380
Website
Mural Oncology PLC is a clinical-stage oncology company whose entire business is focused on discovering and developing immunotherapies that may meaningfully improve the lives of patients with cancer. By leveraging their core competencies in immune cell modulation and protein engineering, It has developed a portfolio of novel, investigational cytokine therapies designed to address areas of unmet need for patients with a variety of cancers. The Company operates as one business segment, which is the business of developing medicines designed to address unmet medical needs of patients in the area of oncology.

Mural Oncology (Mural Oncology) Headlines